Abivax will join the Nasdaq Biotechnology Index starting Monday, December 22, 2025, according to a press release issued on December 18. The NBI tracks the performance of a set of companies listed on the Nasdaq Stock Market and classified as biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Inclusion in this index implies meeting eligibility criteria including minimum market capitalization, average daily trading volume, and tenure as a listed company. The NBI is subject to an annual review in December, and its calculation methodology is based on a modified market capitalization weighting.
A Significant Milestone
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Didier Blondel, CFO of Abivax, described this inclusion as a significant milestone for the company, the press release states. According to him, this entry into the index reflects the progress made by the group, particularly in the development of obefazimod, its flagship drug candidate. It also demonstrates increased visibility and perception of Abivax within the global biotechnology community, the company notes.
About Abivax
Abivax is a clinical-stage biotechnology company based in France and the United States, developing therapies aimed at stabilizing the immune response in patients with chronic inflammatory diseases. Its main drug candidate, obefazimod, is currently undergoing phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company has notably conducted the phase 3 ABTECT Induction trials for this indication, according to the press release. The company is listed on Euronext Paris and on the Nasdaq.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
